Find a Research Study

This is a randomized, double-blind, placebo-controlled study that will evaluate the potential of tildacerfont to reduce GC burden in adult subjects with classic CAH who have LLD ≤ A4 ≤ 2.5x ULN and are on supraphysiologic doses of GC therapy (≥30 mg/day and ≤60 mg/day HCe). This will be the first study of tildacerfont to evaluate GC dose reduction. In addition, this study will characterize clinical outcomes after up to 76 weeks of treatment with tildacerfont. An optional Open-Label Extension Period will provide an open-label treatment with tildacerfont at 200 mg QD for up to 240 weeks.

Study early development in infants who have an older sibling with autism.

To find out the effects of a chemical in Stevia on the symptoms of NAFLD.

Understand the experiences of patients and parents in treatment decision making for children with Neuromuscular Scoliosis (NMS).

To better understand the effects of nutrition in early pregnancy on infant growth and development.

The purpose of the study is to learn about how to improve access to care during adolescence/young adulthood and to see if Virtual Team Clinic is an acceptable form of care. Virtual Team Clinic is a new approach to provide care to (middle/high) school aged patients living with Type 1 Diabetes and their families. This new approach consists of Virtual Team Clinic appointments (primarily telemedicine, and/or in person as necessary). The study also incorporates group visits/medical appointments with a multidisciplinary care team (e.g., RD, RN, Social Worker, etc.). Each group will have a special theme and learning experience. You will learn how to better take care of your diabetes, get support from others, and hopefully have fun.

To explore the possibilities of providing weight management services to teenagers through technology.

To find out the effects of tenofovir alafenamide (TAF) on children and adolescents with chronic hepatitis B.

Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.

The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.